Study | Defined sample* | Representative sample† | Follow-up rate > 80%‡ | Follow-up time§ | Prognosis¶ |
---|---|---|---|---|---|
Bakker et al.10 | Yes | No | Yes | Yes | Yes |
Bousema et al.11 | Yes | No | Yes | Yes | Yes |
Breen et al.12 | Yes | No | No | No | No |
Carey et al.13 Sundararajan et al.14 | Yes | Yes | Yes | Yes | Yes |
Carey et al.15 | Yes | Yes | No | Yes | Yes |
Costa et al.16 | Yes | Yes | Yes | Yes | Yes |
Coste et al.17 | Yes | Yes | Yes | Yes | Yes |
Coste et al.18 | Yes | Yes | Yes | Yes | Yes |
Epping-Jordan et al.19 Shaw et al.20 Wahlgren et al.21 Williams et al.22 | Yes | Yes | Yes | Yes | Yes |
Faber et al.23 | Yes | Yes | Yes | Yes | Yes |
Ferguson et al.24,25 | Yes | No | Yes | Yes | Yes |
Gatchel et al.26,27 | Yes | No | No | Yes | No |
Grotle et al.2,28 | Yes | No | Yes | Yes | Yes |
Gurcay et al.29 | Yes | Yes | Yes | Yes | Yes |
Hasenbring et al.30 | Yes | Yes | Yes | Yes | Yes |
Hazard et al.31 Reid et al.32 | No | Yes | Yes | Yes | Yes |
Heneweer et al.33 | Yes | Yes | Yes | Yes | Yes |
Henschke et al.3 | Yes | Yes | Yes | Yes | Yes |
Klenerman et al.34 | Yes | No | No | Yes | Yes |
Koleck et al.35 | Yes | Yes | Yes | Yes | Yes |
Kovacs et al.36 | Yes | No | Yes | No | Yes |
Lehmann et al.37 | Yes | No | Yes | Yes | Yes |
Melloh et al.38 | Yes | Yes | Yes | Yes | Yes |
Poiraudeau et al.39 | Yes | Yes | Yes | Yes | Yes |
Reeser et al.40 | Yes | Yes | No | Yes | Yes |
Schiottz-Christensen et al.41 | Yes | No | Yes | Yes | Yes |
Shaw et al.42-44 | Yes | No | Yes | Yes | Yes |
Sieben et al.45 | Yes | No | No | Yes | Yes |
Sieben et al.46 | Yes | No | No | Yes | Yes |
Suri et al.47 | Yes | Yes | No | No | Yes |
Swinkels-Meewisse et al.48 | Yes | No | No | Yes | Yes |
Thomas et al.49 | Yes | No | Yes | Yes | No |
Valat et al.50 | Yes | No | Yes | No | Yes |
↵* Description of source of patients and inclusion and exclusion criteria.
↵† Participants were selected as consecutive cases.
↵‡ Outcome data were available for at least 80% of participants at one follow-up point.
↵§ At least one prognostic outcome was followed up at three months or later.
↵¶ Raw data, percentages, survival rates or continuous outcome reported.